Enhancing Heart Allograft Function With the OCS Heart System Trial
Condition(s) studied
Investigational drug(s) / intervention(s)
OCS Heart: Preservation of donor hearts with OCS Heart System and novel OCS Solution and OCS Functional Enhancer.
Static Cold Storage (SCS): Preservation of donor hearts with static cold storage.
Study summary
This trial is designed to evaluate the safety and effectiveness of the novel OCS Solution and OCS Functional Enhancer (OFE) to support FDA approval in both DBD and DCD heart transplantation. In addition, this trial will evaluate the performance of the novel OCS Solution and OFE compared to Static Cold Storage (SCS) in DBD heart transplantation to potentially demonstrate superiority.
Eligibility
Primary outcome measure(s)
- Patient and graft survival — 30-day post transplant
The primary endpoint is 30-day patient and graft survival with freedom from moderate or severe LV or RV primary graft dysfunction (PGD) in the first 24 hours post-transplant.
Trial sites (8)
| Facility | City | Region | Status |
|---|---|---|---|
| University of California San Francisco | San Francisco | California | Recruiting |
| Tampa General Hospital | Tampa | Florida | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | Recruiting |
| Mount Sinai | New York | New York | Recruiting |
| Columbia University Irving Medical Center/ New York Presbyterian Hospital | New York | New York | Not Yet Recruiting |
| Westchester Medical Center | Valhalla | New York | Recruiting |
| Duke University | Durham | North Carolina | Recruiting |
| Baylor Scott and White | Dallas | Texas | Recruiting |
More TransMedics trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07145515 on ClinicalTrials.gov ↗ ← All trials in the USA